Trial Profile
A Phase I Study to Evaluate the Pharmacokinetics of MK-7145 Following Single Dose Administration in Patients With Moderate Renal Insufficiency
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 7145 (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 23 Sep 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 May 2013 Planned end date changed from 1 Feb 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 23 May 2013 Planned initiation date changed from 1 Sep 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.